Free tool
Drugs in development
Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations
Drugs in development
3,685
Not FDA-approved
In Phase 3
1,424
Highest phase reached
Matching your filters
21
21 drugs in development
Names, sponsors and conditions come from the trial records. Click a drug for its trials.
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- matched to NNC0487-0111Phase 39 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- ZenagamtidePhase 39 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- CagriSemaCagrilintide B and Semaglutide IPhase 36 trials
Novo Nordisk · Obesity, Diabetes Mellitus, Type 2, Hypertension
- FT-4202EtavopivatPhase 36 trials
Forma Therapeutics, Inc. · Sickle Cell Disease, Thalassemia
- AtebimetinibIMM-1-104, Group APhase 34 trials
Immuneering Corporation · Pancreatic Adenocarcinoma, Advanced Solid Tumor, Malignant Melanoma (Cutaneous)
- ZiltivekimabPhase 34 trials
Novo Nordisk · Acute Myocardial Infarction (AMI), Myocardial Infarction, Heart Failure
- NNC6019-0001Phase 33 trials
Novo Nordisk · Transthyretin Amyloid Cardiomyopathy (ATTR CM)
- Insuline glargine U100reduced, titratedPhase 32 trials
Ascentage Pharma Group Inc. · Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy, Diabetes Mellitus, Type 2
- matched to semaglutidePhase 32 trials
Novo Nordisk · Overweight, Obesity, Diabetes Mellitus, Type 2
- matched to zenagamtidePhase 32 trials
Novo Nordisk · Overweight, Obesity
- SemagludtidePhase 32 trials
Lumos Pharma · Obesity & Overweight, Early Alzheimer's Disease
- matched to CagrilintidePhase 31 trial
Novo Nordisk · Overweight, Obesity, Type 2 Diabetes
- NNC0519-0130Phase 23 trials
Novo Nordisk · Chronic Kidney Disease, Diabetes Mellitus, Type 2, Obesity
- NNC0662-0419Phase 23 trials
Novo Nordisk · Obesity, Diabetes Mellitus, Type 2, Overweight
- CDR132LPhase 22 trials
Novo Nordisk · Heart Failure
- NNC0194-0499Phase 22 trials
Novo Nordisk · Alcohol-related Liver Disease, Non-alcoholic Steatohepatitis
- NNC0662-3168Test product-APhase 21 trial
Novo Nordisk · Overweight, Obesity, Type 2 Diabetes Mellitus
- TrizepatidePhase 21 trial
Novo Nordisk · Diabetes Mellitus, Type 2
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.